NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

Herein, we investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in prostate cancer. Hormone-sensitive prostate cancer cells, (LNCaP) and castration resistant cancer cells (PC3 and PCai1) were treated with NCL1, and LSD1 expression and cell viability were...

Descripción completa

Detalles Bibliográficos
Autores principales: Etani, Toshiki, Suzuki, Takayoshi, Naiki, Taku, Naiki-Ito, Aya, Ando, Ryosuke, Iida, Keitaro, Kawai, Noriyasu, Tozawa, Keiichi, Miyata, Naoki, Kohri, Kenjiro, Takahashi, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413623/
https://www.ncbi.nlm.nih.gov/pubmed/25605246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413623/
https://www.ncbi.nlm.nih.gov/pubmed/25605246

Ejemplares similares